Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment

NCT00241046 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT00241046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00241046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 4
Overall status
Terminated
Start date
April 30, 2002
Completion date
Not reported
Enrollment
13 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer